2018 Endocrine Fellows Series: Type 1 Diabetes Care and Management - Webcast

This course is intended to be completed after viewing the Endocrine Fellows Series: Type 1 Diabetes Care and Management webcast.  Click the button below to view the webcast

View Webcast


The webcast activity 2018 Endocrine Fellows Series: Type 1 Diabetes Care and Management was originally presented on March 13–15, 2018 prior to ENDO 2018 (March 17–20, 2018) in Chicago, Illinois. For details on current and future programs, visit endocrine.org/t1dmfellows.

This activity is supported by a grant from the following supporters: Abbott Diabetes Care Inc.; Dexcom, Inc.; The Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novo Nordisk Inc.


Target Audience

This continuing medical education activity should be of substanial interest to pediatric and adult endocrine fellows, pediatric and adult endocrinologists, primary care and internal medicine physicians, physician's assistants, nurse practitioners and other advanced practice professionals caring for individuals with diabetes. 

Learning Objectives

Upon completion of this educational activity, participants will be able to (or better able to):

  • Differentially diagnose T1D in youth and assess the familial risk of developing T1D
  • Utilize patient education and counseling to motivate patients and their caregivers and promote adherence
  • Apply current clinical information to set appropriate blood glucose targets taking into consideration a patient’s lifestyle, age and condition
  • Evaluate clinical practice guidelines on the prevention, screening and management of comorbidities
  • Explain the neurological consequences of hypoglycemia and hyperglycemia and recognize potential causes
  • Recognize special considerations in the management of diabetes in a trauma or in-patient setting
  • Discuss the important of individualized nutrition plans and goals for patients with T1D
  • Discuss the potential risks and benefits associated with emerging therapies for diabetes

Additional Information

Target Audience: 
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Interpersonal and Communication Skills
Topic Area: 
Diabetes and Glucose Metabolism
Quality Improvement and Healthcare Delivery
General Endocrinology
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 13.25 AMA PRA Category 1 Credits
  • 13.25 CME Certificate of Participation
Course opens: 
Course expires: 

Program Directors

Irl B. Hirsch, MD; University of Washington Sch of Med
Linda M. Siminerio, RN, PhD, CDE; University of Pittsburgh Diabetes Institute


Roy W. Beck, MD, PhD, University of South Florida 
Luisa A. Duran, MD, John Muir Health 
Robert H. Eckel, MD, University of Colorado
Alison B. Evert MS, RD, CDE, University of Washington
Carla J. Greenbaum, MD, Benaroya Research Institute
Janet B. McGill, MD, University of Washington
Elizabeth R. Seaquist, MD, University of Minnesota 
Craig E. Taplin, MD, Seattle Children’s Hospital
Guillermo E. Umpierrez, MD, Emory University
Amisha Wallia, MD, Northwestern University 
Jill A. Weissberg-Benchell, PhD, CDE, Northwestern University


As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.


The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Irl B. Hirsch, MD (Chair): Consultant, Abbott Diabetes Care, Adocia, Roche, Intarcia, BigFoot; Principal Investigator, Medtronic Diabetes
Robert H. Eckel, MD: Consultant, Sanofi Aventis, Regeneron Pharmaceuticals; Novo Nordisk
Carla J. Greenbaum, MD: Consultant, Bristol-Myers Squibb, Novo Nordisk.; Principal Investigator, Janssen Pharmaceuticals, Novo Nordisk
Janet B. McGill, MD: Consultant, Aegerion, Bayer, Dexcom, Intarcia, Novo Nordisk; Speaker, Aegerion, Dexcom, Janssen Pharmaceuticals, Mannkind, Principal Investigator, AstraZeneca, Novartis
Elizabeth R. Seaquist, MD: Advisor, Eli Lilly, ADA, ABIM; Consultant, Eli Lilly, Sanofi, Zucara Therapeutics, 360 Marketing Services; Sponsor, Novo Nordisk; Research Grantee, Eli Lilly
Guillermo E. Umpierrez, MD: Advisory Board, Sanofi, Merck & Co.; Principal Investigator, AstraZeneca, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Sanofi
Amisha Wallia, MD: Investigator, Eli Lilly; Consultant, Glytec; Trial Adjudicator, Lexicon Pharmaceuticals

The following faculty reported no relevant financial relationship: Linda M. Siminerio, RN, PhD, CDE (Chair); Roy W. Beck, MD, PhD; Luisa A. Duran, MD; Alison B. Evert, MS, RD, CDE; James S. Hirsch; Craig E. Taplin, MD; Jill A. Weissberg-Benchell, PhD, CDE.

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.


The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

Use of professional judgment: 
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available. 
Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.


The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.


This educational activity is supported by an independent medical educational grant from Abbott Diabetes Care Inc.; Dexcom, Inc.; The Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novo Nordisk Inc.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 13.25 AMA PRA Category 1 Credits
  • 13.25 CME Certificate of Participation